Point72 Hong Kong’s Iovance Biotherapeutics IOVA Stock Holding History

Point72 Hong Kong’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-20,707	Closed	-$198K	–	854
2022 Q3	$198K	Buy	+20,707	New	+$239K	0.01%	1050
2022 Q1	–	Sell	-5,492	Closed	-$105K	–	2078
2021 Q4	$105K	Buy	5,492 +4,441	+423%	+$97.8K	﹤0.01%	1163
2021 Q3	$26K	Sell	1,051 -40,019	-97%	-$943K	﹤0.01%	1652
2021 Q2	$1.07M	Buy	+41,070	New	+$1.07M	0.03%	691
2020 Q3	–	Sell	-3,996	Closed	-$110K	–	1347
2020 Q2	$110K	Buy	+3,996	New	+$131K	0.01%	607
2019 Q4	–	Sell	-27	Closed	–	–	1290
2019 Q3	$0	Sell	27 -590	-96%	-$13K	﹤0.01%	1175
2019 Q2	$15K	Sell	617 -1,402	-69%	-$21.1K	﹤0.01%	819
2019 Q1	$19K	Buy	+2,019	New	+$19.6K	0.01%	685
2018 Q2	–	Sell	-1,996	Closed	-$34K	–	1030
2018 Q1	$34K	Buy	+1,996	New	+$30.2K	0.02%	536

Other funds holding IOVA

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Hong Kong's IOVA Position: Q4 2022 in Review

Point72 Hong Kong sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 20,707 shares — an estimated $198K sold.

Point72 Hong Kong first reported a position in IOVA in Q1 2018 and held it in 9 quarters. The position peaked at $1.07M in Q2 2021. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

Point72 Hong Kong reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Point72 Hong Kong sold 20,707 Iovance Biotherapeutics shares in Q4 2022, an estimated $198K.
Point72 Hong Kong first reported a position in Iovance Biotherapeutics in Q1 2018 and held it in 9 quarters.
Point72 Hong Kong's Iovance Biotherapeutics position peaked at $1.07M in Q2 2021.
218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.